Sign Up Today and Learn More About Prazer Therapeutics Stock
Invest in or calculate the value of your shares in Prazer Therapeutics or other pre-IPO companies through EquityZen's platform.
Prazer Therapeutics Stock
Prazer Therapeutics is a biotechnology company that generates novel therapeutics for refractory diseases.
About Prazer Therapeutics Stock
Founded
2019
Industries
Software, Artificial Intelligence, Data and Analytics
Prazer Therapeutics Press Mentions
Stay in the know about the latest news on Prazer Therapeutics
Novel compound exhibiting anti-inflammatory activity as p38 map kinase …
patents • May 05, 2025
Deals in brief: SoftBank to anchor OpenAI’s USD 40 billion raise, Hoopi secures funding for collectibles push, ShopUp and Sary confirm merger, and more
kr-asia • Apr 10, 2025
J&J leads $20 million series B funding for Korean biotech
thepharmaletter • Apr 02, 2025
Prazer Therapeutics raises $20M; Carisma lets go of most staff
endpts • Apr 01, 2025
Novel compound for degradation of target protein or polypeptide by …
patents • Feb 17, 2025
Prazer Therapeutics Management
Leadership team at Prazer Therapeutics
CEO
Kyung-Soo Inn
Join now and verify your accreditation status to gain access to:
- Prazer Therapeutics Current Valuation
- Prazer Therapeutics Stock Price
- Prazer Therapeutics Management
- Available deals in Prazer Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Prazer Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Prazer Therapeutics Revenue and Financials
- Prazer Therapeutics Highlights
- Prazer Therapeutics Business Model
- Prazer Therapeutics Risk Factors
- Prazer Therapeutics Research Report from SACRA Research
Trading Prazer Therapeutics Stock
How to invest in Prazer Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Prazer Therapeutics through EquityZen funds. These investments are made available by existing Prazer Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Prazer Therapeutics stock?
Shareholders can sell their Prazer Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."